A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy
N/A
This was a non-interventional, retrospective cohort study of patients with ...
Status
Completed
Location
Novartis Pharmaceuticals
Start Date
2022-03-16
Trial ID
NCT05853432
Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients
PHASE2
Men and post- or induced menopausal women with ER\[+\] and/or PgR\[+\], HER...
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
PHASE3
The purpose of this study is to complement Study CBYL719C2301 (SOLAR-1) and...
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
PHASE3
This is a Phase 3, open-label, randomized, clinical trial evaluating the ef...
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
PHASE2
The purpose of this study is to assess the safety and efficacy of alpelisib...